Systemic Therapy for Hereditary Breast Cancers

被引：1
|
作者：
Harvey-Jones, Elizabeth J. [1 ]
Lord, Christopher J. [2 ,3 ]
Tutt, Andrew N. J. [1 ,2 ,4 ]
机构：
[1] Breast Canc Now Res Unit, Guys Hosp Canc Ctr, London SE19RT, England
[2] Kings Coll London, City London Canc Res UK Ctr, London SE19RT, England
[3] CRUK Gene Funct Lab, Inst Canc Res, London SW36JB, England
[4] Breast Canc Now Toby Robins Breast Canc Res Ctr, Inst Canc Res, London SW36JB, England
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2023年 / 37卷 / 01期
关键词：
Hereditary breast cancer; Chemotherapy; PARPi; Drug resistance; Biomarkers; STANDARD NEOADJUVANT CHEMOTHERAPY; PATHOLOGICAL COMPLETE RESPONSE; RANDOMIZED PHASE-II; CELL-FREE DNA; HOMOLOGOUS RECOMBINATION; POLY(ADP-RIBOSE) POLYMERASE; ADJUVANT CAPECITABINE; INHIBITOR RESISTANCE; REVERSION MUTATIONS; GERMLINE MUTATIONS;
D O I：
10.1016/j.hoc.2022.08.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Treatment options for patients with hereditary breast cancers have expanded significantly in the past 20 years. These include a new FDA-licensed approach to adjuvant therapy, olaparib, that improves OS in those with gBRCA1/2m. However, resistance to platinum-based chemotherapy and PARPi in this cohort of patients is an issue that requires considerable focus. We have discussed standard approaches to treatment, but have touched on the expanse of pre-clinical and early clinical work being undertaken which will likely shape future treatments in this field of medicine.
引用
收藏
页码：203 / 224
页数：22
相关论文
共 50 条
  • [1] Hereditary breast and ovarian cancers
    Gevensleben, H.
    Serce, N.
    Buettner, R.
    [J]. PATHOLOGE, 2010, 31 (06): : 438 - 444
  • [2] Hereditary breast and ovarian cancers
    Carroll, June C.
    Cremin, Carol
    Allanson, Judith
    Blaine, Sean M.
    Dorman, Heather
    Gibbons, Clare A.
    Grimshaw, Jeremy
    Honeywell, Christina
    Meschino, Wendy S.
    Permaul, Joanne
    Wilson, Brenda J.
    [J]. CANADIAN FAMILY PHYSICIAN, 2008, 54 (12) : 1691 - 1692
  • [3] Drug therapy for hereditary cancers
    Evgeny N Imyanitov
    Vladimir M Moiseyenko
    [J]. Hereditary Cancer in Clinical Practice, 9
  • [4] Drug therapy for hereditary cancers
    Imyanitov, Evgeny N.
    Moiseyenko, Vladimir M.
    [J]. HEREDITARY CANCER IN CLINICAL PRACTICE, 2011, 9
  • [5] Biology of hereditary breast and ovarian cancers
    Tommasi, S.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 : 7 - 7
  • [6] Hereditary breast cancers seen by the pathologist
    Vincent-Salomon, Anne
    [J]. ANNALES DE PATHOLOGIE, 2010, 30 : S90 - S92
  • [7] Systemic treatment for hereditary cancers: a 2012 update
    Evgeny N Imyanitov
    Tomasz Byrski
    [J]. Hereditary Cancer in Clinical Practice, 11
  • [8] Systemic treatment for hereditary cancers: a 2012 update
    Imyanitov, Evgeny N.
    Byrski, Tomasz
    [J]. HEREDITARY CANCER IN CLINICAL PRACTICE, 2013, 11
  • [9] Cytotoxic and targeted therapy for hereditary cancers
    Iyevleva, Aglaya G.
    Imyanitov, Evgeny N.
    [J]. HEREDITARY CANCER IN CLINICAL PRACTICE, 2016, 14
  • [10] Cytotoxic and targeted therapy for hereditary cancers
    Aglaya G. Iyevleva
    Evgeny N. Imyanitov
    [J]. Hereditary Cancer in Clinical Practice, 14
12345